文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

Secretoneurin在严重脓毒症与脓毒性休克患者中的预后价值:来自意大利白蛋白结局脓毒症研究的数据

Prognostic Value of Secretoneurin in Patients With Severe Sepsis and Septic Shock: Data From the Albumin Italian Outcome Sepsis Study.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论在脓毒性休克患者中,第1天Secretoneurin升高与ICU死亡(OR 2.27)和90天死亡(OR 2.04)独立相关,严重脓毒症无休克者则无此关联。

本研究为多中心、干预性、随机临床试验(意大利白蛋白结局脓毒症研究),纳入540例脓毒性休克和418例严重脓毒症患者,随机接受20%人血白蛋白联合晶体液或单纯晶体液治疗。在随机化后第1、2、7天检测Secretoneurin,并与已建立的危险指数和心脏生物标志物比较对ICU和90天死亡的预后价值。结果显示,第1天Secretoneurin在校正已建立危险因素和心血管生物标志物后,与脓毒性休克患者ICU死亡(OR 2.27,95%CI 1.05-4.93;p=0.04)和90天死亡(OR 2.04,95%CI 1.02-4.10;p=0.04)相关,但在无休克的严重脓毒症患者中无此关联;第2天Secretoneurin同样与ICU死亡(OR 3.11,95%CI 1.34-7.20;p=0.008)和90天死亡(OR 2.69,95%CI 1.26-5.78;p=0.01)相关,并改善脓毒性休克患者的重分类。随机白蛋白给药未影响Secretoneurin与结局之间的关联。作者认为Secretoneurin在血流动力学不稳定的脓毒症患者中提供早期且有力的预后信息。

要点

  • 脓毒性休克患者第1天Secretoneurin与ICU死亡独立相关:OR 2.27(95%CI 1.05-4.93;p=0.04)。
  • 脓毒性休克患者第1天Secretoneurin与90天死亡独立相关:OR 2.04(95%CI 1.02-4.10;p=0.04)。
  • 无休克的严重脓毒症患者中,第1天Secretoneurin与ICU及90天死亡无显著关联。
  • 脓毒性休克患者第2天Secretoneurin与ICU死亡(OR 3.11,95%CI 1.34-7.20;p=0.008)和90天死亡(OR 2.69,95%CI 1.26-5.78;p=0.01)相关,并改善重分类。
  • 随机白蛋白给药未影响Secretoneurin与结局的关联。

适用人群与场景

  • 严重脓毒症或脓毒性休克患者,共540例脓毒性休克、418例严重脓毒症。

研究设计与关键结果

  • 研究设计:多中心、干预性随机临床试验(意大利白蛋白结局脓毒症研究),随机接受20%人血白蛋白联合晶体液或单纯晶体液。
  • 第1天Secretoneurin升高与年龄及血清乳酸、胆红素、肌酐、N末端B型利钠肽原浓度相关。
  • 校正已建立危险因素和心血管生物标志物后,脓毒性休克患者第1天Secretoneurin与ICU死亡相关:OR 2.27(95%CI 1.05-4.93;p=0.04),与90天死亡相关:OR 2.04(95%CI 1.02-4.10;p=0.04)。
  • 无休克的严重脓毒症患者中,第1天Secretoneurin与ICU及90天死亡无显著关联。
  • 脓毒性休克患者第2天Secretoneurin与ICU死亡相关:OR 3.11(95%CI 1.34-7.20;p=0.008),与90天死亡相关:OR 2.69(95%CI 1.26-5.78;p=0.01)。
  • 第2天Secretoneurin通过净重分类指数评估改善脓毒性休克患者的重分类。
  • 随机白蛋白给药未影响Secretoneurin与结局之间的关联。

证据类型、等级与局限

  • 证据类型:多中心、干预性、随机、前瞻性、开放标签临床试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为Secretoneurin在血流动力学不稳定的脓毒症患者中提供早期且有力的预后信息。

指南或共识出处

  • The Albumin Italian Outcome Sepsis(意大利白蛋白结局脓毒症研究)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Secretoneurin directly influences cardiomyocyte calcium handling, and circulating secretoneurin levels seem to improve risk prediction in patients with myocardial dysfunction by integrating information on systemic stress, myocardial function, and renal function. Accordingly, in this study, we hypothesized that secretoneurin would improve risk prediction in patients with sepsis and especially in patients with septic shock as these patients are more hemodynamically unstable.

DESIGN: Multicenter, interventional randomized clinical trial.

SETTING: Multicenter, pragmatic, open-label, randomized, prospective clinical trial testing fluid administration with either 20% human albumin and crystalloids or crystalloid solutions alone in patients with severe sepsis or septic shock (The Albumin Italian Outcome Sepsis).

PATIENTS OR SUBJECTS: In total, 540 patients with septic shock and 418 patients with severe sepsis.

INTERVENTIONS: Either 20% human albumin and crystalloids or crystalloid solutions alone.

MEASUREMENTS AND MAIN RESULTS: We measured secretoneurin on days 1, 2, and 7 after randomization and compared the prognostic value of secretoneurin for ICU and 90-day mortality with established risk indices and cardiac biomarkers in septic shock and severe sepsis. High secretoneurin levels on day 1 were associated with age and serum concentrations of lactate, bilirubin, creatinine, and N-terminal pro-B-type natriuretic peptide. Adjusting for established risk factors and cardiovascular biomarkers, secretoneurin levels on day 1 were associated with ICU (odds ratio, 2.27 [95% CI, 1.05-4.93]; p = 0.04) and 90-day mortality (2.04 [1.02-4.10]; p = 0.04) in patients with septic shock, but not severe sepsis without shock. Secretoneurin levels on day 2 were also associated with ICU (3.11 [1.34-7.20]; p = 0.008) and 90-day mortality (2.69 [1.26-5.78]; p = 0.01) in multivariate regression analyses and improved reclassification in patients with septic shock, as assessed by the net reclassification index. Randomized albumin administration did not influence the associations between secretoneurin and outcomes.

CONCLUSIONS: Secretoneurin provides early and potent prognostic information in septic patients with cardiovascular instability.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Røsjø H, Masson S, Caironi P, et al. Prognostic Value of Secretoneurin in Patients With Severe Sepsis and Septic Shock: Data From the Albumin Italian Outcome Sepsis Study. Crit Care Med. 2018. PMID: 29481425. doi:10.1097/CCM.0000000000003050

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。